134 related articles for article (PubMed ID: 36849332)
21. Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis.
VanDevanter DR; Pasta DJ; Konstan MW
J Cyst Fibros; 2015 Nov; 14(6):763-9. PubMed ID: 25754096
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic beta-lactam dosages and broad-spectrum antibiotics are associated with reductions in microbial richness and diversity in persons with cystic fibrosis.
Hahn A; Burrell A; Chaney H; Sami I; Koumbourlis AC; Freishtat RJ; Crandall KA; Zemanick ET
Sci Rep; 2023 Jan; 13(1):1217. PubMed ID: 36681756
[TBL] [Abstract][Full Text] [Related]
23. Predictors of pulmonary exacerbation treatment in cystic fibrosis.
Sanders DB; Ostrenga JS; Rosenfeld M; Fink AK; Schechter MS; Sawicki GS; Flume PA; Morgan WJ
J Cyst Fibros; 2020 May; 19(3):407-414. PubMed ID: 31257102
[TBL] [Abstract][Full Text] [Related]
24. IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis.
VanDevanter DR; Morris NJ; Konstan MW
J Cyst Fibros; 2016 May; 15(3):372-9. PubMed ID: 26603642
[TBL] [Abstract][Full Text] [Related]
25. BEAT CF pulmonary exacerbations core protocol for evaluating the management of pulmonary exacerbations in people with cystic fibrosis.
Schultz A; McLeod C; Berry S; Marsh J; McKenzie A; Messer M; Wood J; Saville B; Jaffe A; Ranganathan S; Stick S; Wark P; Webb S; Snelling T
Trials; 2023 Mar; 24(1):211. PubMed ID: 36949472
[TBL] [Abstract][Full Text] [Related]
26. Sweat metabolomics before and after intravenous antibiotics for pulmonary exacerbation in people with cystic fibrosis.
Woodley FW; Gecili E; Szczesniak RD; Shrestha CL; Nemastil CJ; Kopp BT; Hayes D
Respir Med; 2022 Jan; 191():106687. PubMed ID: 34864373
[TBL] [Abstract][Full Text] [Related]
27. The effect of antibiotic changes during treatment of cystic fibrosis pulmonary exacerbations.
Zikic A; Ratjen F; Shaw M; Tullis E; Waters V
J Cyst Fibros; 2022 Sep; 21(5):759-765. PubMed ID: 35650003
[TBL] [Abstract][Full Text] [Related]
28. The Elusive Role of Airway Infection in Cystic Fibrosis Exacerbation.
Caverly LJ; VanDevanter DR
J Pediatric Infect Dis Soc; 2022 Sep; 11(Supplement_2):S40-S45. PubMed ID: 36069900
[TBL] [Abstract][Full Text] [Related]
29. Pulmonary exacerbations and acute declines in lung function in patients with cystic fibrosis.
Wagener JS; Williams MJ; Millar SJ; Morgan WJ; Pasta DJ; Konstan MW
J Cyst Fibros; 2018 Jul; 17(4):496-502. PubMed ID: 29685810
[TBL] [Abstract][Full Text] [Related]
30. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.
Sanders DB; Solomon GM; Beckett VV; West NE; Daines CL; Heltshe SL; VanDevanter DR; Spahr JE; Gibson RL; Nick JA; Marshall BC; Flume PA; Goss CH;
J Cyst Fibros; 2017 Sep; 16(5):592-599. PubMed ID: 28460885
[TBL] [Abstract][Full Text] [Related]
31. Bronchodilator responsiveness in cystic fibrosis children treated for pulmonary exacerbations.
Pollak M; Shaw M; Wilson D; Solomon M; Ratjen F; Grasemann H
Pediatr Pulmonol; 2021 Jul; 56(7):2036-2042. PubMed ID: 33830642
[TBL] [Abstract][Full Text] [Related]
32. Antimicrobial Stewardship in Cystic Fibrosis.
Lloyd EC; Cogen JD; Maples H; Bell SC; Saiman L
J Pediatric Infect Dis Soc; 2022 Sep; 11(Supplement_2):S53-S61. PubMed ID: 36069899
[TBL] [Abstract][Full Text] [Related]
33. Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations.
Zemanick ET; Harris JK; Wagner BD; Robertson CE; Sagel SD; Stevens MJ; Accurso FJ; Laguna TA
PLoS One; 2013; 8(4):e62917. PubMed ID: 23646159
[TBL] [Abstract][Full Text] [Related]
34. Frequency and costs of pulmonary exacerbations in patients with cystic fibrosis in the United States.
Rubin JL; Thayer S; Watkins A; Wagener JS; Hodgkins PS; Schechter MS
Curr Med Res Opin; 2017 Apr; 33(4):667-674. PubMed ID: 28058864
[TBL] [Abstract][Full Text] [Related]
35. Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.
Wagener JS; Rasouliyan L; VanDevanter DR; Pasta DJ; Regelmann WE; Morgan WJ; Konstan MW;
Pediatr Pulmonol; 2013 Jul; 48(7):666-73. PubMed ID: 22888106
[TBL] [Abstract][Full Text] [Related]
36. Poor recovery from cystic fibrosis pulmonary exacerbations is associated with poor long-term outcomes.
Sanders DB; Zhao Q; Li Z; Farrell PM
Pediatr Pulmonol; 2017 Oct; 52(10):1268-1275. PubMed ID: 28881091
[TBL] [Abstract][Full Text] [Related]
37. Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.
Heltshe SL; Goss CH; Thompson V; Sagel SD; Sanders DB; Marshall BC; Flume PA
Thorax; 2016 Mar; 71(3):223-9. PubMed ID: 25911223
[TBL] [Abstract][Full Text] [Related]
38. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations.
West NE; Beckett VV; Jain R; Sanders DB; Nick JA; Heltshe SL; Dasenbrook EC; VanDevanter DR; Solomon GM; Goss CH; Flume PA;
J Cyst Fibros; 2017 Sep; 16(5):600-606. PubMed ID: 28457954
[TBL] [Abstract][Full Text] [Related]
39. The use of antimicrobial susceptibility testing in pediatric cystic fibrosis pulmonary exacerbations.
Cogen JD; Whitlock KB; Gibson RL; Hoffman LR; VanDevanter DR
J Cyst Fibros; 2019 Nov; 18(6):851-856. PubMed ID: 31147301
[TBL] [Abstract][Full Text] [Related]
40. Antibiotic duration and changes in FEV
Espel JC; Palac HL; Cullina JF; Clarke AP; McColley SA; Prickett MH; Jain M
BMC Pulm Med; 2017 Nov; 17(1):160. PubMed ID: 29187171
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]